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Received June 11, 2012; accepted September 28, 2012AbstractLung cancer is the leading cause of cancer-related death in the world. Prior to the era of targeted therapy, platinum-based doublet
chemotherapy was the first-line therapy of choice for patients with metastatic non-small-cell lung cancer (NSCLC). The availability of agents
that target epidermal growth factor receptor (EGFR)-tyrosine kinase, as well as inhibitors against anaplastic lymphoma kinase (ALK ) gene
rearrangement or ROS-1 gene rearrangement product, has provided promising clinical benefits in specific subpopulations of NSCLC. At present,
only first-generation EGFR-tyrosine kinase inhibitors (TKIs) (erlotinib and gefitinib) are available for clinical use. Second-generation irre-
versible EGFR-TKIs, such as afatinib, are still in clinical trials. In current clinical practice, EGFR-TKI is the first-line treatment of choice for
metastatic NSCLC patients with tumor EGFR mutation or as salvage therapy in NSCLC patients who received systemic chemotherapy pre-
viously. Platinum-based doublet chemotherapy continues to be the standard of care for those treatment-naı¨ve patients with EGFR wild -type
tumor or unknown EGFR status. Even though all investigators agree with the use of EGFR-TKI as the first-line treatment in tumor EGFR-
mutated patients, only 10e30% of NSCLC patients have mutated EGFR, and there was no obvious survival difference when EGFR-TKIs
were used in a second-line setting versus a first-line treatment in EGFR-mutated patients. Thus, the molecular complexity of lung cancer
emphasizes the need for optimizing treatment by seeking a more personalized approach to care, including searching for driver oncogenes,
managing the emergence of resistance and overcoming that resistance, and optimizing the sequence of treatment. Numerous other novel targeted
agents are now in clinical development, including new agents targeting novel pathways and those that may have the potential to overcome the
limitations or resistance associated with currently available EGFR-TKIs. In this report, we review the clinical data of EGFR-TKIs as molecular-
targeted therapies in NSCLC.
Copyright  2013 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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For patients with metastatic non-small-cell lung cancer
(NSCLC), chemotherapy was considered the standard treat-
ment prior to the era of targeted therapy. Although chemo-
therapy may result in a modest improvement in patient
survival, the overall prognosis of these patients remains
dismal, and the treatment is relatively nonspecific and toxic in* Corresponding author. Dr. Yuh-Min Chen, Department of Chest Medicine,
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1726-4901/$ - see front matter Copyright  2013 Elsevier Taiwan LLC and the C
http://dx.doi.org/10.1016/j.jcma.2013.01.010nature. Therefore, new therapeutic strategies are needed
urgently.
During the past decade, targeted therapies against NSCLC,
especially adenocarcinoma, have exhibited marked achieve-
ments, and resulted in improvement in patient survival, either
progression-free survival (PFS) or overall survival, and an
enhanced quality of life in specific patient populations.1e5
Several driver oncogenes that contribute to lung cancer
progression and metastasis have been identified, and have led
to the discovery of several potential molecular targets
(Fig. 1).1,6e11 Epidermal growth factor receptor (EGFR) and
its signal transduction pathway have undergone the most
active and advanced research. In this report, we review thehinese Medical Association. All rights reserved.
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(TKIs) for molecular-targeted therapies in NSCLC.
2. EGFR signal transduction pathway
EGFR was the first identified member of a family of re-
ceptors known as type I receptor tyrosine kinases (TKs) or
ErbB receptors. The binding of ligands to the extracellular
domain of the EGFR activates the receptor TK and triggers
downstream signaling pathways consisting of a rich multi-
layered network that permits multiple combinatorial
responses.10,12
The TK family has two major downstream signaling
pathways. One is the RaseRafeMAP kinase pathway. The
other important pathway is phosphatidylinositol 3-kinase and
the downstream protein-serine/threonine kinase Akt. Another
route for signaling is via the stress-activated protein kinase
pathway, involving protein kinase C and Jak/Stat.12
3. EGFR inhibition
There are several potential strategies for targeting EGFR.13
Of these approaches, monoclonal antibodies (MoAbs) and
TKIs are in the most advanced stages of clinical develop-
ment.1,2,14 At the level of downstream receptor-dependent
signaling pathways, EGFR antibodies and TKIs seem to
have similar effects. Both strategies result in an efficient
blockade of the main EGFR signal transduction pathways.13,15Fig. 1. Histologic and molecular subtypes of NSCLC. Adenocarcinoma is the most
(top). Both adenocarcinoma and squamous cell carcinoma can be subdivided furth
alternations are different between Asian and Caucasian populations; for example,
female never-smokers showed that 76.2% tumors harbored EGFR mutations, 4.6%
mutations.6 From ROS1 rearrangements in lung cancer: A new genomic subset of lu
Oncology 30, p. 878. Copyright 2012, Name of Copyright Holder. Adapted with pe
Hutchinson, Nature Medicine, 2012, 18, p.350. Copyright 2012, Name of Copyrigh
Cancer Research, volume number, page number, Copyright 201x, Name of Copyr
ceptor; NSCLC ¼ non-small-cell lung cancer.As a result, anti-EGFR MoAbs and TKIs interfere with a
number of key cellular functions regulated by the receptor,
which explains their antitumor effects (Fig. 2).13,16,17 Since the
discovery of a high degree of association between tumor
EGFR-activated mutations and the efficacy of EGFR-TKIs,
the latter have been studied extensively in the treatment of
tumor EGFR-mutated NSCLC1,2 however, anti-EGFR MoAbs
has been studied less extensively and successfully used in only
one Phase III trial of chemo-naı¨ve NSCLC in combination
with doublet chemotherapy.1,2,184. First-generation EGFR-TKI
Gefitinib (Iressa) and erlotinib (Tarceva) are two first-
generation EGFR-TKIs that have already been approved for
clinical use. These two agents are small molecules that
reversibly target EGFR-TK. Their side effects are usually mild
to moderate, and consist of a dose-dependent skin rash and
diarrhea. In Phase I studies both drugs have resulted in
objective responses in heavily pretreated NSCLC patients,
when used as single agents.19,20
Two randomized Phase II trials [Iressa Dose Evaluation in
Advanced Lung Cancer 1 (IDEAL 1) and IDEAL 2] with two
dose levels of gefitinib (250 mg/d and 500 mg/d) have been
carried out in patients with advanced NSCLC who had pro-
gressed after previous chemotherapy. The IDEAL 1 study
showed an 18.7% response rate and marked improvement in
disease-related symptoms.21 The 250 mg/d dose was as activecommon histologic subtype of NSCLC, followed by squamous cell carcinoma
er, based on different somatic genomic alterations. The frequency of genomic
driver oncogene analysis from 349 resected lung adenocarcinomas of Chinese
HER2 mutations, EML-4ALK fusions, 2% KRAS mutations, and 0.6% BRAF
ng adenocarcinoma by P.A. Ja¨nne, M. and Meyerson, 2012, Journal of Clinical
rmission; from Chipping away at the lung cancer genome by W. Pao and K.E.
t Holder. Adapted with permission; and from Name of author/s, 201x, Clinical
ight Holder. Adapted with permission. EGFR ¼ epidermal growth factor re-
Fig. 2. EGFR signaling pathway. The processes of ligandereceptor and
receptorereceptor interactions lead to the activation of intracellular pathways
that regulate cellular survival/apoptosis, proliferative activity, and other func-
tions that together promote malignant behavior. EGFR antibody binds to EGFR
and inhibits ligand binding (e.g., EGF). Tyrosine kinase inhibitors (such as
gefitinib and erlotinib) bind the intracellular tyrosine kinase domain and block
its transduction pathway. EGF ¼ epidermal growth factor; EGFR ¼ epidermal
growth factor receptor.
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IDEAL 2 study tumor objective response rates of 12% and 9%
were observed for the 250 mg/d and 500 mg/d groups,
respectively.22 The toxicity profiles of the IDEAL 2 study
were similar to those of the IDEAL 1 study. A Phase III
randomized study [Iressa Survival Evaluation in Lung Cancer
(ISEL)] included 1692 patients who were randomly assigned
to receive gefitinib or a placebo.23 In this study, gefitinib failed
to prolong survival statistically compared to the placebo in the
overall population (median: 5.6 vs. 5.1 months; p ¼ 0.11).
However, a subgroup analysis of East Asian patients showed
that those who received gefitinib (n ¼ 235) had superior sur-
vival than those who were given a placebo (n ¼ 107) (median:
9.5 vs. 5.5 months; p ¼ 0.012). A Phase III randomized study
with a noninferiority design comparing gefitinib with doce-
taxel in 1433 NSCLC patients who received 1 platinum-
based regimens met the predefined noninferiority criterion ofTable 1
Four large Phase III randomized studies of chemotherapy with or without TKI (gefi
with advanced NSCLC (total 4361 patients).
Study Patients (n) Regimen Re
INTACT 1 1093 Cisplatin and gemcitabine, or
with gefitinib (250 or 500 mg/d)
44
INTACT 2 1037 Carboplatin and paclitaxel, or
with gefitinib (250 or 500 mg/d)
42
TRIBUTE 1079 Carboplatin and paclitaxel, or
with erlotinib
19
TALENT 1172 Cisplatin and gemcitabine, or
with erlotinib
29
INTACT ¼ Iressa NSCLC Trial Assessing Combination Treatment; NSCLC ¼ non-
TALENT ¼ Tarceva Lung Cancer Investigation; TKI ¼ tyrosine kinase inhibitor; TRoverall survival [hazard ratio (HR): 1.020; 95% confidence
interval (CI): 0.905e1.150; median survival: 7.6 vs. 8.0
months], suggesting that gefitinib is a valid treatment for
pretreated patients having molecular-unselected advanced
NSCLC.24
Erlotinib, an orally available quinazoline, is also a selective
EGFR-TKI. It is the first EGFR-TKI to demonstrate an in-
crease in survival of patients with advanced NSCLC in a Phase
III randomized trial (BR. 21).4 In this study, patients treated
with erlotinib had a response rate of 8.9% and a statistically
significant increase in median (6.7 vs. 4.7 months) and 1-year
survival (31% vs. 21%) compared to patients receiving a
placebo.4 Side effects of erlotinib were mild and acceptable,
consisting mainly of skin toxicity and diarrhea. Results of a
Phase III randomized trial comparing erlotinib with docetaxel
in the second-line treatment of NSCLC patients with EGFR
wild type tumor have recently been presented at the American
Society of Clinical Oncology (ASCO) 2012 annual meeting.25
5. EGFR-TKI combined with chemotherapy
Four large Phase III randomized studies of chemotherapy
with or without TKI (gefitinib or erlotinib) in patients with
advanced chemo-naı¨ve NSCLC were conducted to determine
whether or not gefitinib or erlotinib can enhance the antitumor
effect of chemotherapy and thus prolong patient survival more
than that with chemotherapy alone (Table 1).26e29 In the Iressa
NSCLC Trial Assessing Combination Treatment (INTACT) 1
study, the chemotherapy regimen was cisplatin plus gemcita-
bine. Patients were assigned randomly to chemotherapy plus a
placebo, chemotherapy plus gefitinib 250 mg/d, or chemo-
therapy plus gefitinib 500 mg/d. A total of 1093 patients were
enrolled in the study. The results showed no significant dif-
ferences in response rate, PFS, and overall survival across the
three assigned groups. In the INTACT 2 trial, 1037 patients
were enrolled in a similarly designed trial, with a chemo-
therapy regimen consisting of carboplatin and paclitaxel.
Again, there were no differences in response rate, PFS, and
overall survival across the three groups. Like gefitinib,
chemotherapy with/without erlotinib was also used in chemo-
naı¨ve NSCLC patients [Tarceva Responses in Conjunction
with Paclitaxel and Carboplatin (TRIBUTE) and Tarceva Lung
Cancer Investigation (TALENT) studies]. These studies alsotinib or erlotinib) in clinical or molecular-unselected, treatment-naı¨ve patients
sponse rate (%) PFS (mo) OS (mo)
.8 vs. 50.3 vs. 49.7 6.0 vs. 5.8 vs. 5.5
( p ¼ 0.76)
10.9 vs. 9.9 vs. 9.9
( p ¼ 0.45)
vs. 41 vs. 37 5.0 vs. 5.3 vs. 4.6
( p ¼ 0.562)
9.9 vs. 9.8 vs. 8.7
( p ¼ 0.64)
.3 vs. 21.5 4.9 vs. 5.1 ( p ¼ 0.36) 10.5 vs. 10.6
( p ¼ 0.95)
.9 vs. 31.5 5.7 vs. 5.5 ( p ¼ 0.74) 10.3 vs. 10.0
( p ¼ 0.49)
small-cell lung cancer; PFS ¼ progression-free survival; OS ¼ overall survival;
IBUTE ¼ Tarceva Responses in Conjunction with Paclitaxel and Carboplatin.
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chemotherapy. In the TRIBUTE study, 1059 chemo-naı¨ve
advanced NSCLC patients were randomized to receive pacli-
taxel/carboplatin with or without erlotinib.28 In the TALENT
study, 1172 chemo-naı¨ve advanced NSCLC patients were
randomized to receive cisplatin plus gemcitabine with or
without erlotinib.29
The results of these four well-controlled trials, which
included a total of 4361 patients, have clearly demonstrated
that, in chemo-naı¨ve NSCLC patients, the addition of gefitinib
or erlotinib to conventional chemotherapy does not enhance
the clinical benefit of chemotherapy alone. Thus, in molecu-
larly unselected NSCLC patients, erlotinib or gefitinib should
not be used in combination with cytotoxic chemotherapy as
the first-line therapy.26e29
6. EGFR mutation
Following the treatment with EGFR-TKIs, examinations of
tumor EGFR status by immunohistochemistry, fluorescence
in-situ hybridization (FISH), or EGFR mutation status by
DNA sequencing were performed and the results were corre-
lated with treatment response and survival status.1,12,30 EGFR
mutation status had its best correlation with treatment
efficacy,1,12,31e33 followed by FISH examinations.30,33 In
addition to predicting response to EGFR-TKIs, EGFR muta-
tions may also be a prognostic factor.1,12,34e36
In two large series reports on the epidemiology of EGFR
mutations,37,38 Shigematsu and Gazdar37 found that all muta-
tions reportedwere somatic and occurredwithin exons 18e21 of
the EGFR gene, which encodes part of the intracellular TK
domain. Three different types of mutations associated with
sensitivity to EGFR-TKIs have been found: (1) in-frame de-
letions in exon 19, which was the most common mutation and
accounted for 46% of all EGFR mutations; (2) missense muta-
tions in exon 18, 20, or 21, which were the secondmost common
mutations and accounted for 41% of all EGFR mutations,
particularly the single-nucleotide substitutions L858R in exon
21; and (3) in-frame duplications/insertions in exon 20, ac-
counting for 5% of all mutations. They found that EGFR mu-
tations appear to be associated with sensitivity to EGFR-TKIs,
and also with East Asian ethnicity, female gender, no history of
smoking, and an adenocarcinoma histology. Murray et al38
reviewed the data of 12,244 patients, and 3381 somatic EGFR
mutations were noted. Exon 19 mutations occurred most
frequently (50%), followed by exon 21 (40%), 20 (6%), and 18
(4%) mutations. L858R and delE746-A750 accounted for
32.8% and 24.3% of all mutations, respectively, with 50% of
mutations being exon 19 deletions or “deletional insertions”.
There is a clear association between the presence of mutations
and the response to TKI, with exon 19mutations having the best
response rate (70%), followed by exons 21, 18, and 20, with a
response rate of around 20% or slightly higher.
The median time to disease progression was around 10
months for EGFR-mutated patients who received EGFR-TKI
treatment, with a wide range of differences due to many
possible underlying mechanisms, such as coexisting T790M,c-MET amplification, genomic alterations in chromosome 7p,
and even a proportion of EGFR wild type tumor cells that could
affect PFS.1,2,39e43 For example, Su et al39 from Taiwan per-
formed a study of 107 TKI-naı¨ve NSCLC patients with matrix-
assisted laser desorptioneionization time-of-flight mass
spectrometry, and the results showed that T790Mmight not be a
rare event prior to EGFR-TKI treatment in NSCLC patients with
EGFR-activating mutations. The pretreatment T790M mutation
was associated with shorter PFS when these patients received
EGFR-TKI treatment. However, a recent large Phase III trial had
an unexpected finding: patients with EGFR compound mutants
(exon19deletions orL858RplusT790M) attained themaximum
benefit (PFS and overall survival) from erlotinib treatment
compared to those with exon 19 deletions or L858R alone,44
suggesting a need for more sensitive assays to detect EGFR
compound mutants and for studies of EGFR-TKIs targeting the
EGFR T790M mutation. Whole genome sequencing may pro-
vide a greater understanding of the genetic factors involved in the
differences in survival status. A recent study also showed that an
increased expression of the NF-kB inhibitor predicted improved
response and survival in EGFR-mutant lung cancer patients
treated with EGFR-TKI.45 TheBIM polymorphism is associated
with EGFR-TKI intrinsic resistance, and prediction of PFS with
EGFR-TKI treatment has also been reported recently.46 Paz-
Ares et al47 reported a pooled analysis of published studies in
patients with EGFR-mutated NSCLC who were treated with
chemotherapy or EGFR-TKIs. The results showed that the
overall median PFS was 13.2 months with erlotinib, 9.8 months
with gefitinib, and 5.9 months with chemotherapy.
Several methods are used to detect EGFR mutations in lung
cancer specimens.48 The sensitivity of direct sequencing is
relatively poor and requires more mutant DNA to detect EGFR
mutations in specimens (10e25% mutant DNA). Thus, when
EGFR mutation was analyzed using the direct DNA sequence
method, a 10e20% objective response rate, sometimes even
higher in specific clinical populations, was noted in EGFR
wild type NSCLC patients.49e51 High-sensitivity methods,
such as the Scorpion amplified refractory mutation system
(ARMS) and peptide nucleic acid-locked nucleic acid (PNA-
LNA) polymerase chain reaction (PCR) clamp methods, are
more sensitive and able to detect 1% mutant DNA in the
specimens.3,48,52,53 However, direct sequencing can detect new
mutations, while the PNA-LNA PCR clamp and Scorpion
ARMS methods can detect only known mutations.48,52e54
Tumor samples used for EGFR mutation analysis were usu-
ally obtained from biopsies of primary lung lesions or meta-
static lesions. Samples from pleural effusion, circulating tumor
cells, and serum or plasma-free DNA could also be used for
mutation analysis.48,52,54e58
7. First-line EGFR-TKI treatment in tumor EGFR-
mutated NSCLC patients
Recent Phase III randomized clinical trials showed a high
level of efficacy of EGFR-TKIs as a first-line treatment for
EGFR-mutated NSCLC, compared with platinum-based dou-
blets, in terms of prolongation of PFS, better quality of life,
Table 2
Five Phase III randomized trials comparing first-line EGFR-TKI and chemotherapy treatment in clinically or molecularly selected NSCLC patients with EGFR
active mutations.
I-PASS NEJSG WJTOG3405 OPTIMAL (CTONG 0802) EURTAC
G P þ Cb ( p*) G P þ Cb ( p*) G D þ Cis ( p*) E Ge þ Cb ( p*) E Platinum based ( p*)
RR (%) 71.2 47.3 (<0.001) 73.7 30.7 (<0.001) 62.1 32.2 (<0.0001) 83 36 (<0.001) 54.5 10.5
PFS (mo) 9.5 4.9 (<0.001) 10.8 5.4 (<0.001) 9.2 6.3 (<0.0001) 13.1 4.6 (<0.001) 9.4 5.2 (<0.001)
OS (mo) 21.6 21.9 (0.99) 30.5 23.6 (0.31) UA UA UA UA 22.9 18.8 (0.42)
*The p values when comparing the EGFR-TKI group.
Cb ¼ carboplatin; Cis ¼ cisplatin; D ¼ docetaxel; E ¼ erlotinib; EGFR ¼ epidermal growth factor receptor; EURTAC ¼ European erlotinib versus chemotherapy;
G ¼ gefitinib; Ge ¼ gemcitabine; I-PASS ¼ Iressa Pan Asia study; NEJSG ¼ North-East Japan study group; NSCLC ¼ non-small-cell lung cancer; OPTIMAL ¼
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive NSCLC; OS ¼ overall survival; P ¼ paclitaxel;
PFS ¼ progression-free survival; RR ¼ response rate; TKI ¼ tyrosine kinase inhibitor; UA ¼ unavailable; WJTOG3405 ¼West Japan thoracic oncology group 3405.
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first-line treatment with erlotinib or gefitinib is recommended
for patients with activating EGFR mutations.63 The median
PFS of EGFR-mutated patients who received EGFR-TKI was
approximately 10 months, but 5e6 months if they received
platinum-based doublet chemotherapy. However, overall sur-
vival was not significantly different between EGFR-mutated
patients who received EGFT-TKI and those who received
chemotherapy as the first-line treatment.62,64e67 If the EGFR
mutation status is negative or unknown, then cytotoxic
chemotherapy is preferred as the first-line treatment.
8. EGFR-TKI as maintenance therapy after first-line
chemotherapy
Two randomized Phase III studies including molecular-
unselected patients showed that EGFR-TKI was not indi-
cated as an adjuvant or a maintenance therapy in postoperative
patients or in stage III patients after chemoradiotherapy.68,69
A retrospective study of patients with resected stages IeIII
lung adenocarcinomas harboring EGFR exon 19 deletions or
exon 21L858R found a trend toward improvement in disease-
free survival among individuals who received EGFR-TKI as
an adjuvant therapy compared to those who did not receive
it.70 However, further study is needed to confirm these results.
In stage IV NSCLC patients with an unselected or unknown
EGFR mutation status, EGFR-TKI was also not indicated for
combinationwith platinum-baseddoublet chemotherapy followed
by EGFR-TKI alone as a maintenance therapy.26e29 However,
whether or not chemotherapy intercalated with EGFR-TKI is
useful is still controversial, with conflicting results in Phase II
randomized trials71,72 and Phase III results still pending.73
Erlotinib has been tested as a maintenance therapy in a
randomized Phase III trial [sequential tarceva in unrectable
NSCLC (SATURN)] including 889 molecular-unselected pa-
tients with NSCLC who were without disease progression after
four cycles of platinum-based doublet chemotherapy.74 There
was a 29% risk reduction in PFS (HR: 0.71, p < 0.0001) fa-
voring erlotinib maintenance treatment, and a survival
advantage of 12 months for erlotinib versus 11.1 months for
placebo ( p ¼ 0.0088). Among patients with a squamous his-
tology (n ¼ 360), those in the erlotinib group experienced a
statistically significantly longer PFS than those receivingplacebo (HR: 0.76; 95% CI: 0.60e0.95), but did not experi-
ence a statistically significant difference in overall survival
(HR: 0.86; 95% CI: 0.68e1.10). Among patients with an
adenocarcinoma histology (n ¼ 401), those in the maintenance
erlotinib group experienced a statistically significant
improvement in PFS (HR: 0.60; 95% CI: 0.48e0.75) and
overall survival (HR: 0.77; 95% CI: 061e0.97). EGFR mu-
tation analysis was performed on approximately 40% of pa-
tients. Although patients with wild type EGFR had a small
PFS benefit from erlotinib (HR: 0.78; p ¼ 0.0185), the most
striking difference favoring erlotinib was observed in EGFR-
mutated patients (HR: 0.10; p<0.0001). Similarly, a Phase III
study (Avastin (bevacizumab) and Tarceva (erlotinib) as
combined first-line maintenance treatment (ATLAS)) testing
bevacizumab with or without erlotinib as a maintenance
therapy in patients who received initial platinum-based ther-
apy in combination with bevacizumab and, in the absence of
disease progression, found that the bevacizumab plus erlotinib
maintenance treatment showed prolongation of PFS (4.8 vs.
3.7 months, p ¼ 0.0012) but not of overall survival.75
A West Japan Thoracic Oncology Group trial investigated
six cycles of platinum-based double-agent therapy compared
with three cycles of platinum-based double-agent chemo-
therapy followed by gefitinib until disease progression.76 The
median number of chemotherapy cycles in both groups was
three. The patients in the sequential group experienced a sig-
nificant prolongation of PFS compared with those in the
chemotherapy-alone group, but no statistically significant
difference was observed in overall survival. A randomized
study performed in China, that was similar to SATURN,
showed that PFS was significantly longer with gefitinib
(n ¼ 148) than with placebo (n ¼ 148) (median PFS: 4.8 vs.
2.6 months; HR: 0.42; 95% CI: 0.33e0.55; p < 0$0001).77
However, overall survival was not different. HR for PFS was
0.17 (95% CI: 0.07e0.42) in EGFR-mutated patients and 0.86
(95% CI: 0$48e1.51) in EGFR wild type patients. No benefit
in PFS was noted in patients with SCC.77
9. Second-generation, irreversible EGFR-TKIs
Currently, new novel compounds, which bind irreversibly
to EGFR-TK, are being tested in clinical studies.78,79 These
agents, including afatinib (BIBW 2992), PF0299804, and
254 Y.-M. Chen / Journal of the Chinese Medical Association 76 (2013) 249e257neratinib (HKI 272), are in advanced stages of clinical testing.
These irreversible EGFR-TKIs seem to be active not only in
activating mutations, but also in mutations associated with
secondary resistance, such as T790M. A preliminary report of
afatinib plus cetuximab in NSCLC patients with acquired
resistance to erlotinib or gefitinib revealed that confirmed
partial responses were seen in 8/22 evaluable patients (36%),
including 4/13 (29%) confirmed partial responses in T790M-
positive NSCLC. Enrollment has now begun for an
80-patient expanded cohort.80
Afatinib is an irreversible EGFR and HER2 inhibitor. A
Phase II trial of afatinib treatment in 129 EGFR-mutated
adenocarcinoma patients showed that 79 (61%) of 129 pa-
tients had an objective response to afatinib. Of them, 70 (66%)
of 106 patients with the two common activating EGFR mu-
tations (deletion 19 or L858R) had an objective response, as
did nine (39%) of 23 patients with less common mutations.78
Afatinib was compared with placebo in a randomized Phase
III trial (LUX-Lung 1) conducted in 585 patients with
advanced lung adenocarcinoma pretreated with one or two
prior chemotherapies and at least 12 weeks of prior gefitinib or
erlotinib.79 Although there was no significant difference in
overall survival (primary end point) between the treatment
studies, there was a 2.2-month PFS advantage favoring afati-
nib (1.1 vs. 3.3 months; p < 0.0001). Preliminary results of a
Phase III randomized trial comparing afatinib with peme-
trexate plus cisplatin treatment in treatment-naı¨ve tumor
EGFR-mutated patients (LUX Lung-3) have recently been
published in an annual meeting of ASCO.81
PF00299804, an irreversible pan-HER inhibitor, was
compared with erlotinib in a Phase II randomized trial with
188 patients with NSCLC who had received one or two prior
chemotherapies but not EGFR-TKI treatment. PF00299804,
compared with erlotinib, showed an improved response rate
(17.1% vs. 4.3%; p ¼ 0.008) and median PFS (2.9 vs. 1.9
months, p ¼ 0.017). However, there was an imbalance in the
number of EGFR-mutated patients between the two groups,
with nearly twice as many patients in the PF00299804 group
as in the erlotinib group (20.2% vs. 11.7%).82 Neratinib is also
an irreversible pan-ErbB receptor TKI. A Phase II study of
neratinib revealed that the objective response rate was only 3%
in 91 previously EGFR-TKI-treated, EGFR-mutated, NSCLC
patients with no wild type EGFR who received EGFR-TKI
prior to responding to neratinib treatment (n ¼ 48). Also,
none of the 28 EGFR-TKI-naı¨ve adenocarcinoma patients
with light smoking histories (20 pack-years) responded to
treatment. Patients with known T790M also did not respond to
neratinib treatment. However, three of four patients with an
exon 18 G719X EGFR mutation had a partial response. Thus,
although neratinib showed low activity in patients with prior
benefit from TKIs and in TKI-naı¨ve patients, it may yet be
beneficial for patients with the rare G719X EGFR mutation.83
10. Overcoming acquired EGFR-TKI resistance
Despite the initial success of gefitinib or erlotinib in the
treatment of NSCLC with EGFR mutations, most patientswill ultimately develop disease progression (acquired resis-
tance to EGFR-TKI).84 At present, there are several treatment
choices if EGFR-TKI treatment fails, including salvage
chemotherapy, use of other approved EGFR-TKIs, entering
second-line targeted therapy trials, or chemotherapy plus the
original EGFR-TKI. Among these options, only salvage
chemotherapy is considered as a standard salvage therapy or
a better choice.2
The therapeutic success of reversible EGFR-TKIs in EGFR-
mutant NSCLC is mainly limited by the development of drug
resistance, such as a T790M mutation, which accounts for half
of the cases, and by mesenchymal epithelial transition factor
(MET) amplification in 5e20% of the patients.85e87 In a study
of 93 patients in whom a rebiopsy was performed after the
failure of EGFR-TKI treatment, 58 (62%) patients had a T790M
mutation. Patients with the T790M mutation had significantly
longer postprogression survival than those with acquired resis-
tance and no T790M mutation.88 The T790M mutation has also
been detected occasionally in tumor specimens from NSCLC
patients with no prior exposure to EGFR-TKIs,39,88,89 although
the prevalence of this pre-existing T790M can vary depending
on the detection method employed.39
Regarding MET amplification-induced drug resistance, in-
vestigators recently found that MET amplification was present
in a small fraction of tumor cells prior to EGFR-TKI treat-
ment, and an increased expression of hepatocyte growth factor
was found in tumor specimens with acquired resistance to
EGFR-TKI.90 Cell line study also showed that combination
treatment with MET and EGFR kinase inhibitors might be
beneficial in MET-amplified NSCLC by reducing the selection
of drug-resistant clones.91 These findings support the rationale
for an initial combination therapy, specifically in a molecu-
larly defined cohort of patients with evidence of pre-existing
MET amplification.90,91
In addition to these genetic alterations, loss of insulin-like
growth factor (IGF)-binding proteins with activation of IGF-
1Rb/IRS-1 signaling also drives EGFR-TKI resistance in
EGFR wild-type cancer cell lines.92 Other possible mecha-
nisms included phosphoinositide 3-kinase autoactivation
through an Erb3 pathway or loss of PTEN expression, a small-
cell lung cancer transformation, and an epithelial to mesen-
chymal transition.87,93e95
In conclusion, EGFR mutation is the most common driver
oncogene found in Asian NSCLC patients. Every effort should
be exercised to ascertain the EGFR mutation status in our
patients prior to initiating systemic treatment. First-line
treatments with EGFR-TKI, such as gefitinib or erlotinib,
should be given to EGFR-mutated stage IV NSCLC patients.
First-line platinum-based doublet chemotherapy is the treat-
ment of choice for NSCLC patients with wild-type or un-
known EGFR mutation status. For patients with unknown
EGFR mutation status, first-line EGFR-TKI treatment could
be considered in those with a poor performance status of 3 or
4, because chemotherapy is not an appropriate treatment for
these patients. Median PFS of EGFR-TKI is around 10
months, and strategies to overcome acquired resistance to
EGFR-TKI are in ongoing development.
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